GLP-1 News — Week of October 19, 2026
The GLP-1 stories that mattered this week — what happened, and what each one means for you if you're using or considering these medications. Every story links to its primary source, and nothing here is influenced by advertisers.
FDA shortage list no longer includes Ozempic, Wegovy, Mounjaro, or Zepbound
A review of the FDA Drug Shortage database shows that as of October 17, 2026, semaglutide and tirzepatide injections sold as Ozempic, Wegovy, Mounjaro, and Zepbound are not listed as being in shortage at the federal level. This marks a shift from 2022–2024, when multiple strengths of these drugs were officially on the shortage list, although patients still report intermittent stock issues at individual pharmacies or for specific doses. (2026-10-17)
What this means for you: You should not count on federal shortage status to justify compounded alternatives anymore, because regulators currently consider the branded injections to be adequately supplied. You may still run into local stock gaps, so plan refills early, ask pharmacies about alternate strengths, and be prepared to call around if your usual location is out of a particular dose.
Source: GLP1-US
Related on Metabolic Ledger: /cost/glp1-drug-shortage-guide
Rhode Island Medicaid stops paying for GLP-1 drugs when used only for weight loss
An updated HealthInsurance.org explainer notes that Rhode Island's Medicaid program ended coverage for GLP-1 medications like Wegovy, Saxenda, Zepbound, and Foundayo when prescribed solely for weight loss as of October 1, 2026. This move mirrors earlier 2026 cutbacks in California, New Hampshire, Pennsylvania, and South Carolina and joins Michigan's shift to much stricter body mass index criteria for obesity only coverage. (2026-10-16)
What this means for you: If you are on Rhode Island Medicaid and taking a GLP-1 only for obesity, you may now have to pay the full price or stop the drug unless you qualify under another covered diagnosis such as type 2 diabetes or cardiovascular disease. Before your next refill, check your state Medicaid rules and talk with your prescriber about whether your documented conditions and records could support continued coverage or an appeal.
Source: HealthInsurance.org
Related on Metabolic Ledger: /cost/medicaid-coverage-glp1
Updated tracker shows only a small minority of Medicaid programs still cover GLP-1s for obesity
WellChosen Health's state by state tracker, updated through October 18, 2026, reports that roughly 10 out of 51 Medicaid programs still cover at least one GLP-1 drug for weight loss. The tool synthesizes recent state decisions to end coverage for obesity only indications and highlights inconsistencies between official state documents and managed care plan lists, underscoring how fluid and confusing policies remain. (2026-10-18)
What this means for you: If you rely on Medicaid, you should now assume that GLP-1 coverage for obesity alone is the exception rather than the rule, even if your state covered it earlier in 2026. Before starting or continuing a drug like Wegovy, Zepbound, or Foundayo under Medicaid, confirm the current written policy for your state and plan, and factor in that coverage could be rolled back mid year, exposing you to sudden costs or treatment disruption.
Source: WellChosen Health
Related on Metabolic Ledger: /cost/medicaid-coverage-glp1
KFF analysis underscores legal leeway for states to exclude GLP-1 obesity drugs from Medicaid
A Kaiser Family Foundation report from January 2026, now being widely cited in October policy discussions, documents that only 13 Medicaid programs covered GLP-1 drugs for obesity treatment at the start of the year and that several have since reduced or eliminated this coverage. The report explains that federal law allows states to exclude weight loss drugs from Medicaid while still requiring coverage for GLP-1s used for conditions like type 2 diabetes or certain cardiovascular and sleep apnea indications. (2026-01-16)
What this means for you: You should expect ongoing swings in Medicaid coverage for GLP-1s used for obesity, because states have broad discretion to add or drop these benefits in response to budget pressures. To protect your access, it helps to track how your weight, blood sugar, blood pressure, or sleep apnea respond to treatment and to work with your clinician on strong medical necessity documentation if your state moves to limit coverage.
Source: KFF
Related on Metabolic Ledger: /cost/medicaid-coverage-glp1
Novo Nordisk reports CagriSema benefits across the menopause transition in women with obesity
Novo Nordisk presented post hoc analyses from the REDEFINE 1 trial of its investigational combination drug CagriSema, focusing on women with overweight or obesity before, during, and after menopause. At The Menopause Society 2026 meeting, the company reported that weight loss and metabolic improvements appeared broadly similar across menopausal stages, a group that often faces weight gain and higher cardiometabolic risk. (2026-10-20)
What this means for you: Nothing changes yet for your current treatment, because CagriSema is still in trials and not FDA approved. If you are in your 40s to 60s and struggling with menopause related weight gain, this adds to the case that future combination drugs may be particularly relevant to you; you can ask your specialist whether you might qualify for upcoming studies or whether to factor CagriSema into longer term planning.
Source: Novo Nordisk
Related on Metabolic Ledger: /after-glp1/glp1-and-menopause
CagriSema data at EASD 2026 highlights appetite, organ, and bone effects in obesity and diabetes
Novo Nordisk's late September press release, still central to October EASD coverage, describes new data on its investigational CagriSema combination in people with obesity and type 2 diabetes. The analyses emphasize reductions in appetite and food related thoughts as well as favourable signals on liver, kidney, and bone health markers, positioning CagriSema as part of a pipeline that aims to improve multi organ cardiometabolic health beyond weight loss alone. (2026-09-30)
What this means for you: This does not affect your medication options now, but it is a clue that successors to semaglutide and tirzepatide may target multiple hormones with stronger weight loss and possible liver or bone benefits. If you have fatty liver disease, early kidney issues, or low bone density and are not getting the results you need from current drugs, it may be worth following CagriSema trials and discussing research opportunities or future switches with your clinician over the next few years.
Source: Novo Nordisk
Related on Metabolic Ledger: /drugs/cagrisema